Login to Your Account



FDA Approves Horizant for PHN; GSK Promotion Role 'Up in Air'

By Catherine Shaffer
Staff Writer

Friday, June 8, 2012
Shares of XenoPort Inc. plunged 9.6 percent Thursday as investors frantically shorted the stock that had run up to more than $6 in anticipation of the PDUFA date for Horizant (gabapentin enacarbil) extended-release tablets for postherpetic neuralgia (PHN) in adults, an event that triggered a $10 million milestone payment from partner GlaxoSmithKline plc.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription